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PP-001 Chemotherapeutic implications of peptide
deformylase against experimental tuberculosis
A. Sharma, S. Sharma*, G.K. Khuller. Department of
Biochemistry, Post Graduate Institute of Medical Education
and Research, Chandigarh-160012, India
Objectives: The present study explores the potential of
known peptide deformylase (PDF) inhibitors as chemother-
apeutic agents against experimental tuberculosis.
Methods: Several PDF inhibitors like BB-3497, actinonin,
1, 10-phenanthroline, hydroxylamine hydrochloride, and
galardin that have shown their potential against other
bacteria were selected for their evaluation against
Mycobacterium tuberculosis.
Results: Based on in vitro studies, the minimum inhibitory
concentration (MIC) of PDF inhibitors was found to be
in the range of 0.2 74mg/L, and among different PDF
inhibitors, BB-3497 and 1, 10-phenanthroline exhibited
potent antimycobacterial activity. In addition PDF inhibitors
exhibited bacteriostatic mode of inhibition. Ex vivo studies
with BB-3497 and actinonin led to reduction of colony
forming units (cfu) by almost 2 log10 units at their
MIC concentration. Moreover, reduction of cfu by BB-
3497 was comparable to that of isoniazid. Under short
course chemotherapy, BB-3497 was signiﬁcantly active and
comparable to isoniazid. Extended chemotherapy of 6 weeks
with BB-3497 and actinonin revealed BB-3497 to be more
potent under in vivo condition. Interestingly, BB-3497 and
actinonin exhibited synergism with isoniazid and rifampicin
under in vitro conditions and during chemotherapy of
murine tuberculosis.
Conclusions: Peptide deformylase inhibitors like BB-3497
and actinonin showed their efﬁcacy against Mycobacterium
tuberculosis under in vitro, ex vivo and in vivo conditions
and BB-3497 was found to be the most efﬁcacious
inhibitor. Thus PDF from M. tuberculosis appears to be an
attractive target for development of new antibiotics against
tuberculosis.
PP-002 Comparison of prevalence of pulmonary
tuberculosis among diabetics and non diabetics
patients in primary care centre
A. Shahzad*. Ch-KD&RL Bhakker, Pakistan
Objective: The aim of present study was to see the
Comparison of Prevalence of Pulmonary Tuberculosis among
known diabetic and non diabetics outdoor patients in
primary care centre.
Design: An observational study conducted on known diabetic
and non diabetic outdoor patients.
Place and Duration of Study: The study was conducted in
primary care centre at Ch-KD&RL Bhakker, Pakistan from
Feb 2007 Sept 2007.
Patients and Methods: One hundred and ﬁfty known
diabetic outdoor patients were screened for pulmonary
tuberculosis and compared with 150 non diabetic controls
seen consecutively during the same period.
Results: The study showed the prevalence of pulmonary
tuberculosis among diabetic patients was 10% compared to
non-diabetic patients who had prevalence of 3% (P-Value
<0.001) which showed 8% higher risk in diabetic patients.
Conclusion: It was concluded that problem of pulmonary
tuberculosis is signiﬁcant in diabetic patients as compared
to non diabetic patients. The results suggest that we should
screen diabetic patients with respiratory complaints for
pulmonary tuberculosis at primary care centre and start
early anti tuberculosis treatment.
PP-003 Evaluation on the cellular immunity of M.
tuberculosis in HIV/AIDS and tuberculosis
co-infected individuals in China
S. Zhang1 *, L.Y. Shao1, C.Y. Meng1, Ying Wang1, L.L. Huang1,
Yun Wang1, X.H. Weng1, W.H. Zhang1, Y.Y. Xu2, H.Y. Hu2.
1Department of Infectious Diseases, Huashan Hospital,
Fudan University, Shanghai, China, 2Department of
Infectious Diseases, No. 1 People Hospital, Honghe State,
Yunnan, China
Objective: To investigate the prevalence of latent
tuberculosis co-infection in HIV/AIDS population and
evaluate the cellular immunity of M. tuberculosis (MTB)
in latent tuberculosis or active tuberculosis and HIV/AIDS
co-infected individuals in China.
Methods: The ELISPOT assay (T SPOT-TB assay) induced by
speciﬁc peptide antigens, ESAT-6 and CFP-10, was employed
to detect MTB speciﬁc T cells in blood samples from 100 HIV-
positive individuals in Yunnan Province. Flow cytometry was
performed on all the participants to detect absolute CD4+
and CD8+ T cell counts.
Results: The prevalence of latent tuberculosis co-infection
in HIV-positive individuals without any clinical evidence of
active tuberculosis was 67.65% in China. The CD4+ and
CD8+ T cell counts in HIV-positive individuals with latent
tuberculosis co-infection were similar to those in patients
who had HIV infection only, while those cell counts in HIV-
positive individuals with active tuberculosis co-infection
were dramatically decreased (P < 0.01). The ESAT-6 and
CFP-10 speciﬁc spot-forming cells in HIV-positive individuals
with active tuberculosis co-infection were signiﬁcantly
less than those in HIV-positive individuals with latent
tuberculosis co-infection (P < 0.01).
Conclusion: In China, there was a high prevalence of
latent tuberculosis co-infection in HIV-positive individuals
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without any clinical evidence of active tuberculosis. The
total cellular immunity of HIV-positive individuals with
latent tuberculosis co-infection wasn’t impaired, while the
speciﬁc immune response to MTB in them was signiﬁcantly
increased. Either the total cellular immunity or the speciﬁc
immune response to MTB in those with active tuberculosis
co-infection was seriously destructed.
Fig. 1. The ESAT-6 speciﬁc spot-forming cells of T SPOT-
TB assay in different population groups. Group HIV+TB-:
patients with HIV infection only, no MTB co-infection, n = 22;
Group HIV+LTB: patients with HIV infection and latent
tuberculosis co-infection, n = 46; Group HIV+TB: patients
with HIV infection and active tuberculosis co-infection,
n = 32. SFCs: spot-forming cells. The short transverse line
represents mean of SFCs in different population groups.
HIV+TB-: 0 SFCs/106 PBMC; HIV+LTB: 92 SFCs/106 PBMC;
HIV+TB: 31 SFCs/106 PBMC.
Fig. 2. The CFP-10 speciﬁc spot-forming cells of T SPOT-
TB assay in different population groups. Group HIV+TB-:
patients with HIV infection only, no MTB co-infection, n = 22;
Group HIV+LTB: patients with HIV infection and latent
tuberculosis co-infection, n = 46; Group HIV+TB: patients
with HIV infection and active tuberculosis co-infection,
n = 32. SFCs: spot-forming cells. The short transverse line
represents mean of SFCs in different population groups.
HIV+TB-: 1 SFCs/106 PBMC; HIV+LTB: 109 SFCs/106 PBMC;
HIV+TB: 82 SFCs/106 PBMC.
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PP-004 Hepatitis B prevention for nurses
M. Zandi1 *, S.M. Alavian2. 1Tarbiat Modares University,
Tehran, Iran, 2Baqiyatallah University of Medical Sciences,
Baqiyatallah Research Center for Gastroenterology & Liver
Disease (BRCGL), Tehran, Iran
Hepatitis B virus infection is a major global public health
problem but it is preventable with safe and effective vaccine
which has available for decade. This risk of acquisition
of infection appears to be great in health care workers,
especially in nurses and particularly during training, when
exposure is maximal. The experience of an exposure to
blood or body ﬂuids during the ﬁnal two years of study is
high. Nurses have an important role in disease control. It is
recommended that greater awareness is needed in society
about the ways of transmission of hepatitis B infection and
preventive measures should be improved. An increase in
awareness of the population of the risks of HBV infection
and of potential preventive measures will deﬁnitely improve
the control of HBV infection nationwide and will eventually
decrease the associated health care costs.
PP-005 Attaching importance to the management of
chronic HBV carriers
J.Z. Guo, Z. Liu *. Beijing Ditan Hospital, Beijing 100011,
China
Background: Almost 130 million Chinese people are
chronically infected with HBV. We need to pay more
attention to the chronic hepatitis B carriers in order to
administer them very well. So we study the inﬂuence
factors on liver inﬂammation and ﬁbrosis through the clinical
examination and liver biopsy.
Methods: Ultrasound guided needle biopsies were collected
from 158 chronic hepatitis B carriers. Chi square test was
used for statistics analysis.
Results: The average age of the 158 chronic hepatitis B
carriers is 31.7± 9.12 years old. 36 cases (22.8%) are G 2;
35 cases (22.2%) are S 2, 5 cases are G3 (among them
4 cases are S3, and 1 case is S4), 9 cases are S3, and one
is S4. 49 cases (31%) need treatments. There are signiﬁcant
differences on liver ﬁbrosis in gender, age and HBeAg. Among
the chronic hepatitis B carriers, the degree of liver ﬁbrosis is
more severe in that who is male (c2 = 4.17, P < 0.05). Though
the G 2 percentage of male exceed female, there have
no statistic difference (c2 = 3.26, P < 0.05). The carriers who
are older than 30 years are more severe than who are no
more than 30 years (c2 = 5.02, P < 0.05). The carriers who are
HBeAg negative are more severe than those who areHBeAg
positive on ﬁbrosis (HBVDNA is positive) (c2 = 4.52, P < 0.05).
There has no signiﬁcant difference on liver inﬂammation.
Conclusions: People consider that the chronic hepatitis B
carriers with normal ALT need not to be treated
traditionally. But we found that some carriers would develop
into cirrhosis and/or HCC. The state of illness aggravates
silently. So we can’t judge the illness by liver function
test, we should depend on the whole individually. There
are nearly 1/3 carriers with obvious inﬂammation and/or
ﬁbrosis, especially people who is male, older than 30 years
or whose HBeAg is negative (HBVDNA is positive), the degree
of ﬁbrosis is more severe. So we should pay more attention
to them, enhance the management, and treat them with
anti-virus and anti-ﬁbrosis therapy at necessary in order to
decrease the possibility of progressing to end-stage liver
diseases.
